Dr Arnaud Desfeux is the founder of omicX, launching the OMICtools platform in 2013. He currently leads the company as CEO and President of the Strategic Board. Arnaud obtained a PhD in Cellular Biology with a specialization in Neurosciences at the University of Rouen, France. He has prior experience in marketing and studied Operational Management.
Dr Phillippe Dro has over 20 years of entrepreneurial experience in the life science industry, and has played a pivotal role in executing several strategic transactions both in biotech and medtech companies. After starting in R&D and operations, he worked in Finance at Novartis, before joining Jago Holding, which was later sold to SkyePharma Ltd. He was part of the founding team of Axovan AG in Basel, a GPCR platform which was lately sold to Actelion AG (ATLN:SW). He joined EndoArt SA, a medical technology company in Lausanne as Chairman and CEO until its acquisition by Allergan (AGN:NYSE). After a time as venture capitalist, he joined the Zurich-based vaccine developer GlycoVaxyn AG, overseeing its development until its acquisition by GSK in 2015. Philippe is on the Board of Directors of several biotech and medtech companies. He has a Pharmacy degree and an MBA from the ESC Lyon/Cranfield School of Management.
Prof. Esteban Cvitkovic’s career spanning 50 years has focused on early stage development of anticancer agents. He has been instrumental in supporting the registration of several oncology drugs. Highlights of his career include founding two oncology-specialized CROs, and co-founding the biotech OncoEthix which was sold to Merck. Prof. Cvitkovic serves on numerous Scientific Boards, including the Foundation Nélia & Amadeo Barletta and several biotechs. He has been an advisor to Index Ventures and Medicxi among others.
Mr François Guisset currently serves as the Managing Director at Normandie Participations SAS SCR, a private equity and venture capital firm, and contributed to the creation of this regional investment fund. He has acquired over 15 years of international B2B and B2C experience. Mr Guisset graduated from the ESC Paris Business School and Sciences Po Paris (Institut for Political Studies, Paris).
Dr David Sourdive is a co-founder and Board member of Cellectis, and currently serves as Executive Vice President of Technical Operations. Prior to joining Cellectis, he acquired 10 years of experience in industrial program management at the French Department of Defense (DGA). Dr Sourdive has served on various Board of Directors, including the Mediterranean Institute for Life Sciences. He graduated from the École Polytechnique, and obtained his PhD at Institut Pasteur before a research fellowship at Emory University. His management training is from the HEC (Challenge Plus).